Concepedia

A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease

Detlef Schuppan, Markku Mäki, Knut E. A. Lundin, Jorma Isola, Tina Friesing-Sosnik, Juha Taavela, Alina Popp, Jari Koskenpato, Jost Langhorst, Øistein Hovde,

New England Journal of Medicine · 2021 · 206 citations · 26 references

DOIFull text

Open access

Abstract

In this preliminary trial, treatment with ZED1227 attenuated gluten-induced duodenal mucosal damage in patients with celiac disease. (Funded by Dr. Falk Pharma; CEC-3 EudraCT number, 2017-002241-30.).

References

26

Identification of tissue transglutaminase as the autoantigen of celiac disease

Walburga Dieterich, Tobias Ehnis, Michael Bauer et al. · Nature Medicine · 1997 · 2K citations

, , +8

The Oslo definitions for coeliac disease and related terms

Jonas F. Ludvigsson, Daniel A. Leffler, Julio C. Bai et al. · Gut · 2012 · 1.7K citations · Full text

Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease

Øyvind Molberg, Stephen N. McAdam, Roman Körner et al. · Nature Medicine · 1998 · 1.2K citations

, , +11

Increasing prevalence of coeliac disease over time

Sini Lohi, K. Mustalahti, Katri Kaukinen et al. · Alimentary Pharmacology & Therapeutics · 2007 · 743 citations · Full text

Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity.

Y. van de Wal, Y Kooy, Peter A. van Veelen et al. · PubMed · 1998 · 491 citations

, , +21